GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Other Income (Expense)

Vifor Pharma AG (LTS:0RPD) Other Income (Expense) : CHF-37 Mil (TTM As of Dec. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Other Income (Expense)?

Vifor Pharma AG's other income expense for the Vifor Pharma AG's pretax income for the six months ended in Dec. 2021 was CHF-35 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2021 was CHF-37 Mil.

Vifor Pharma AG Other Income (Expense) Historical Data

The historical data trend for Vifor Pharma AG's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Other Income (Expense) Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.90 53.80 -1.60 -20.20 -36.70

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.60 -2.40 -17.80 -1.40 -35.30

Vifor Pharma AG Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vifor Pharma AG  (LTS:0RPD) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Vifor Pharma AG (LTS:0RPD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Other Income (Expense)
Comparable Companies
XSWX:SFZN XSWX:PPGN XTER:MRK ZTS TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 VTRS SHSE:600196 NBIX NSE:DIVISLAB SZSE:000963 HKSE:03692 XTAE:TEVA SZSE:000661 SZSE:300142 SHSE:600085
Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Website
https://www.viforpharma.com
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines